David Hooper

Minimus developed a novel injection treatment for patients with disc herniations. It's called Triojection, which is now licensed to SpinaFX. Based on existing data in the scientific literature, Triojection improves patient care and reduces cost. Here are a few of the things that we did at Minimus. • Created an investor group consisting of physicians and medical device executives from the US, Europe and Middle East. Including an investment from the State of Texas, Minimus raised approximately $3.75M. • Developed a dedicated, cross-functional team to develop, build and validate the product. • Filed and received numerous patents in the US and abroad. • Established an ISO 13485 Quality Management System that passed numerous audits. • CE Marked our product as a treatment for disc herniation. • Conducted a multi-center, randomized clinical study in three countries comparing Triojection to surgical discectomy (clincialtrials.gov NCT02525120). The data from that study are being written up for publication. • Currently seeking funds to continue operations or sell the technology. Keywords: angel investments, new business development, project management, , product development, CE Mark, ISO 13485, quality, spine, clinical trials, regulatory affairs, business analyst, FDA, statistics, technical writing, medical device